Digital Therapeutics for Chronic Disease Management in Saudi Arabia: A Structured Narrative Review and Comparative Policy Analysis
Health Innovation Reports · 15.10.2026 · 2 (4) · 64-74
DOI: 10.64048/hir.v2n4.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Innovation Reports, online erschienen am 15.10.2026. Verfasst von Ali Alam. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Saudi Arabia faces a rising chronic disease burden, with diabetes prevalence near 23.1% and extensive cardiometabolic comorbidity. Digital therapeutics (DTx) are widely proposed as a scalable complement to chronic care, but the evidence strength, regulatory and reimbursement maturity, and economic case for adoption have not previously been assessed against a defined standard.
Methods
We conducted a structured narrative review, informed by SANRA, of peer-reviewed clinical and health-services literature (PubMed/MEDLINE, Scopus, Web of Science; 2015–2026) alongside regulatory and policy documents from Saudi Arabia, Germany, England, and the United States. Clinical-effectiveness evidence was appraised for study design, sample size, comparator, follow-up duration, and funding independence. A five-dimension framework (regulatory classification, reimbursement, data governance and interoperability, post-market surveillance, and time-to-decision) benchmarked Saudi Arabia against three reference jurisdictions, and CFIR categorized barriers.
Results
Saudi Arabia's national digital health infrastructure (Sehhaty, Wasfaty, Nphies, Seha Virtual Hospital) provides an enabling but insufficient foundation for DTx integration. The SFDA's 2025 guidance (MDS-G27) establishes a classification pathway but, unlike Germany's DiGA fast-track, does not yet link approval to reimbursement. Clinical-effectiveness evidence is directionally positive but concentrated in industry-funded, non-Saudi populations, with few randomized studies; economic evaluations are scarce outside high-income settings, and no Saudi- or Gulf-specific cost-effectiveness analysis was identified. Seven candidate policy pillars (regulatory pathway, reimbursement, data governance, interoperability, workforce development, digital equity, post-market surveillance) are organized around these findings, not presented as a stand-alone proposal.
Conclusion
A national DTx policy framework for Saudi Arabia is timely, but components should be sequenced to evidence rather than advanced uniformly. Closing the regulatory–reimbursement gap, commissioning Saudi-specific clinical and economic evaluation, and building post-market surveillance capacity are prerequisites for adoption, not parallel companions. The seven pillars are a structured agenda for deliberation and research, not a finished roadmap.
Zitieren
APA
Alam, A. (2026). Digital Therapeutics for Chronic Disease Management in Saudi Arabia: A Structured Narrative Review and Comparative Policy Analysis. Health Innovation Reports, 2(4), 64-74. https://doi.org/10.64048/hir.v2n4.009
Vancouver
Alam A. Digital Therapeutics for Chronic Disease Management in Saudi Arabia: A Structured Narrative Review and Comparative Policy Analysis. Health Innovation Reports. 2026;2(4):64-74. doi:10.64048/hir.v2n4.009
BibTeX
@article{Alam2026,
author = {Alam, Ali},
title = {Digital Therapeutics for Chronic Disease Management in Saudi Arabia: A Structured Narrative Review and Comparative Policy Analysis},
journal = {Health Innovation Reports},
year = {2026},
volume = {2},
number = {4},
pages = {64--74},
doi = {10.64048/hir.v2n4.009}
}
EUVIMED